Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
164M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
31.5M
-
Shares change
-
+203K
-
Total reported value, excl. options
-
$48.8M
-
Value change
-
+$392K
-
Put/Call ratio
-
0.16
-
Number of buys
-
21
-
Number of sells
-
-21
-
Price
-
$1.55
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q4 2023
69 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q4 2023.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.5M shares
of 164M outstanding shares and own 19.2% of the company stock.
Largest 10 shareholders include BVF INC/IL (6.6M shares), TANG CAPITAL MANAGEMENT LLC (6.55M shares), VANGUARD GROUP INC (4.9M shares), ACADIAN ASSET MANAGEMENT LLC (2.65M shares), RENAISSANCE TECHNOLOGIES LLC (1.33M shares), Laurion Capital Management LP (1.09M shares), Bronte Capital Management Pty Ltd. (920K shares), MILLENNIUM MANAGEMENT LLC (794K shares), JACOBS LEVY EQUITY MANAGEMENT, INC (791K shares), and GEODE CAPITAL MANAGEMENT, LLC (703K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.